Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Sep 4;83(7):906–913. doi: 10.1054/bjoc.2000.1374

Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists

I Chatzistamou 1,2, A V Schally 1,2, B Sun 1,2, P Armatis 1, K Szepeshazi 1,2
PMCID: PMC2374679  PMID: 10970693

Abstract

Receptors for bombesin are present on human ovarian cancers and bombesin-like peptides could function as growth factors in this carcinoma. Therefore, we investigated the effects of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095 on the growth of human ovarian carcinoma cell line OV-1063, xenografted into nude mice. Treatment with RC-3940-II at doses of 10 μg and 20 μg per day s.c. decreased tumour volume by 60.9% (P< 0.05) and 73.5% (P< 0.05) respectively, after 25 days, compared to controls. RC-3095 at a dose of 20 μg per day reduced the volume of OV-1063 tumours by 47.7% (P = 0.15). In comparison, luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix at a dose of 100 μg per day caused a 64.2% inhibition (P< 0.05). RT-PCR analysis showed that OV-1063 tumours expressed mRNA for bombesin receptor subtypes BRS-1, BRS-2, and BRS-3. In OV-1063 cells cultured in vitro, GRP(14–27) induced the expression of mRNA for c- jun and c- fos oncogenes in a time-dependent manner. Antagonist RC-3940-II inhibited the stimulatory effect of GRP(14–27) on c- jun and c- fos in vitro. In vivo, the levels of c- jun and c- fos mRNA in OV-1063 tumours were decreased by 43% (P< 0.05) and 45% (P = 0.05) respectively, after treatment with RC-3940-II at 20 μg per day. Exposure of OV-1063, UCI-107 and ES-2 ovarian carcinoma cells to RC-3940-II at 1 μM concentration for 24 h in vitro, extended the latency period for the development of palpable tumours in nude mice. Our results indicate that antagonists of bombesin/GRP inhibit the growth of OV-1063 ovarian cancers by mechanisms that probably involve the downregulation of c- jun and c- fos proto-oncogenes. © 2000 Cancer Research Campaign

Keywords: cancer therapy, bombesin/GRP antagonists, LH-RH antagonist, ovarian tumours, c- jun, c- fos

Full Text

The Full Text of this article is available as a PDF (190.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajusz S., Csernus V. J., Janaky T., Bokser L., Fekete M., Schally A. V. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res. 1988 Dec;32(6):425–435. doi: 10.1111/j.1399-3011.1988.tb01373.x. [DOI] [PubMed] [Google Scholar]
  2. Bernhardt G., Reile H., Birnböck H., Spruss T., Schönenberger H. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol. 1992;118(1):35–43. doi: 10.1007/BF01192309. [DOI] [PubMed] [Google Scholar]
  3. Bologna M., Festuccia C., Muzi P., Biordi L., Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 1989 May 1;63(9):1714–1720. doi: 10.1002/1097-0142(19900501)63:9<1714::aid-cncr2820630912>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  4. Cai R. Z., Reile H., Armatis P., Schally A. V. Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12664–12668. doi: 10.1073/pnas.91.26.12664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carney D. N., Cuttitta F., Moody T. W., Minna J. D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987 Feb 1;47(3):821–825. [PubMed] [Google Scholar]
  6. Chegini N., Rong H., Dou Q., Kipersztok S., Williams R. S. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab. 1996 Sep;81(9):3215–3221. doi: 10.1210/jcem.81.9.8784072. [DOI] [PubMed] [Google Scholar]
  7. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  8. Draoui M., Chung P., Park M., Birrer M., Jakowlew S., Moody T. W. Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells. Peptides. 1995;16(2):289–292. doi: 10.1016/0196-9781(94)00173-1. [DOI] [PubMed] [Google Scholar]
  9. Emons G., Müller V., Ortmann O., Schulz K. D. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):199–206. doi: 10.1016/s0960-0760(97)00189-1. [DOI] [PubMed] [Google Scholar]
  10. Halazonetis T. D., Georgopoulos K., Greenberg M. E., Leder P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell. 1988 Dec 2;55(5):917–924. doi: 10.1016/0092-8674(88)90147-x. [DOI] [PubMed] [Google Scholar]
  11. Halmos G., Schally A. V. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):956–960. doi: 10.1073/pnas.94.3.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Halmos G., Wittliff J. L., Schally A. V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995 Jan 15;55(2):280–287. [PubMed] [Google Scholar]
  13. Horowitz A. T., Treves A. J., Voss R., Okon E., Fuks Z., Davidson L., Biran S. A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. Oncology. 1985;42(5):332–337. doi: 10.1159/000226056. [DOI] [PubMed] [Google Scholar]
  14. Jungwirth A., Galvan G., Pinski J., Halmos G., Szepeshazi K., Cai R. Z., Groot K., Schally A. V. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate. 1997 Aug 1;32(3):164–172. doi: 10.1002/(sici)1097-0045(19970801)32:3<164::aid-pros2>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  15. Jungwirth A., Pinski J., Galvan G., Halmos G., Szepeshazi K., Cai R. Z., Groot K., Vadillo-Buenfil M., Schally A. V. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 1997 Jun;33(7):1141–1148. doi: 10.1016/s0959-8049(97)00072-5. [DOI] [PubMed] [Google Scholar]
  16. Jungwirth A., Schally A. V., Halmos G., Groot K., Szepeshazi K., Pinski J., Armatis P. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer. 1998 Mar 1;82(5):909–917. doi: 10.1002/(sici)1097-0142(19980301)82:5<909::aid-cncr16>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  17. Kiaris H., Schally A. V., Sun B., Armatis P., Groot K. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene. 1999 Nov 25;18(50):7168–7173. doi: 10.1038/sj.onc.1203213. [DOI] [PubMed] [Google Scholar]
  18. Kim H. J., Evers B. M., Banker N. A., Greeley G. H., Jr, Hellmich M. R., Thompson J. C., Townsend C. M., Jr Novel expression and regulation of gastrin gene in human ovarian cancer cell line, SW626. Dig Dis Sci. 1998 Jul;43(7):1465–1473. doi: 10.1023/a:1018846311239. [DOI] [PubMed] [Google Scholar]
  19. Koppán M., Halmos G., Arencibia J. M., Lamharzi N., Schally A. V. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer. 1998 Oct 1;83(7):1335–1343. doi: 10.1002/(sici)1097-0142(19981001)83:7<1335::aid-cncr10>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  20. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1. doi: 10.3322/canjclin.49.1.8. [DOI] [PubMed] [Google Scholar]
  21. Levi F., Lucchini F., Negri E., Boyle P., La Vecchia C. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur J Cancer. 1999 Oct;35(10):1477–1516. doi: 10.1016/s0959-8049(99)00154-9. [DOI] [PubMed] [Google Scholar]
  22. Liebow C., Crean D. H., Lee M. T., Kamer A. R., Mang T. S., Schally A. V. Synergistic effects of bombesin and epidermal growth factor on cancers. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3804–3808. doi: 10.1073/pnas.91.9.3804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Markwalder R., Reubi J. C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999 Mar 1;59(5):1152–1159. [PubMed] [Google Scholar]
  24. Miyazaki M., Lamharzi N., Schally A. V., Halmos G., Szepeshazi K., Groot K., Cai R. Z. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Eur J Cancer. 1998 Apr;34(5):710–717. doi: 10.1016/s0959-8049(97)10123-x. [DOI] [PubMed] [Google Scholar]
  25. Moody T. W., Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci. 1993;52(14):1161–1173. doi: 10.1016/0024-3205(93)90098-n. [DOI] [PubMed] [Google Scholar]
  26. Nagalla S. R., Barry B. J., Creswick K. C., Eden P., Taylor J. T., Spindel E. R. Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6205–6209. doi: 10.1073/pnas.92.13.6205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Qin Y., Ertl T., Cai R. Z., Halmos G., Schally A. V. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 1994 Feb 15;54(4):1035–1041. [PubMed] [Google Scholar]
  28. Qin Y., Halmos G., Cai R. Z., Szoke B., Ertl T., Schally A. V. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol. 1994;120(9):519–528. doi: 10.1007/BF01221028. [DOI] [PubMed] [Google Scholar]
  29. Radulovic S., Cai R. Z., Serfozo P., Groot K., Redding T. W., Pinski J., Schally A. V. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Protein Res. 1991 Dec;38(6):593–600. doi: 10.1111/j.1399-3011.1991.tb01545.x. [DOI] [PubMed] [Google Scholar]
  30. Shirahige Y., Cai R. Z., Szepeshazi K., Halmos G., Pinski J., Groot K., Schally A. V. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomed Pharmacother. 1994;48(10):465–472. doi: 10.1016/0753-3322(94)90007-8. [DOI] [PubMed] [Google Scholar]
  31. Siegfried J. M., Han Y. H., DeMichele M. A., Hunt J. D., Gaither A. L., Cuttitta F. Production of gastrin-releasing peptide by a non-small cell lung carcinoma cell line adapted to serum-free and growth factor-free conditions. J Biol Chem. 1994 Mar 18;269(11):8596–8603. [PubMed] [Google Scholar]
  32. Spindel E. R., Giladi E., Segerson T. P., Nagalla S. Bombesin-like peptides: of ligands and receptors. Recent Prog Horm Res. 1993;48:365–391. doi: 10.1016/b978-0-12-571148-7.50017-8. [DOI] [PubMed] [Google Scholar]
  33. Sun B., Halmos G., Schally A. V., Wang X., Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000 Mar 1;42(4):295–303. doi: 10.1002/(sici)1097-0045(20000301)42:4<295::aid-pros7>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  34. Szepeshazi K., Schally A. V., Halmos G., Groot K., Radulovic S. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst. 1992 Dec 16;84(24):1915–1922. doi: 10.1093/jnci/84.24.1915. [DOI] [PubMed] [Google Scholar]
  35. Szepeshazi K., Schally A. V., Halmos G., Lamharzi N., Groot K., Horvath J. E. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10913–10918. doi: 10.1073/pnas.94.20.10913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Thurnher M., Radmayr C., Ramoner R., Ebner S., Böck G., Klocker H., Romani N., Bartsch G. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer. 1996 Sep 27;68(1):1–7. doi: 10.1002/(SICI)1097-0215(19960927)68:1<1::AID-IJC1>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  37. Tomayko M. M., Reynolds C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148–154. doi: 10.1007/BF00300234. [DOI] [PubMed] [Google Scholar]
  38. Yano T., Pinski J., Groot K., Schally A. V. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 1992 Aug 15;52(16):4545–4547. [PubMed] [Google Scholar]
  39. Yano T., Pinski J., Halmos G., Szepeshazi K., Groot K., Schally A. V. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7090–7094. doi: 10.1073/pnas.91.15.7090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Yano T., Pinski J., Szepeshazi K., Halmos G., Radulovic S., Groot K., Schally A. V. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 1994 Feb 15;73(4):1229–1238. doi: 10.1002/1097-0142(19940215)73:4<1229::aid-cncr2820730417>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES